Item 2.02 Results of Operations and Financial Condition.
Please see the disclosure relating to certain preliminary financial results of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers
(b) On
Item 7.01 Regulation FD Disclosure.
On
In addition, on the conference call management intends to announce certain
preliminary financial results for the quarter ended
1
The Company expects that the conference call and ensuing Q&A session will
include certain forward-looking statements regarding the therapeutic potential
of, and future development plans for, NKTR-358, NKTR-255 and our other drug
candidates in research programs, the timing of the initiation of clinical
studies and the availability of clinical data for our drug candidates, our
expectations (including our expected charges and cost savings) following our
corporate restructuring, reorganization and workforce reduction, and our
expected working capital our cash runway. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based
only on our current beliefs, expectations and assumptions regarding the future
of our business, future plans and strategies, anticipated events and trends, the
economy and other future conditions. Because forward-looking statements relate
to the future, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are outside of our
control. Our actual results may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any of these
forward-looking statements. Important factors that could cause our actual
results to differ materially from those indicated in the forward-looking
statements include, among others: (i) our statements regarding the therapeutic
potential of NKTR-358, NKTR-255 and our other drug candidates are subject to
change as research and development continue to generate new safety and efficacy
data; (ii) NKTR-358, NKTR-255 and our other drug candidates are investigational
agents and continued research and development for these drug candidates is
subject to substantial risks, including negative safety and efficacy findings in
ongoing studies (notwithstanding positive findings in earlier preclinical and
clinical studies); (iii) NKTR-358, NKTR-255 and our other drug candidates are in
various stages of clinical development and the risk of failure is high and can
unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of
the commencement or end of clinical trials and the availability of clinical data
may be delayed or unsuccessful due to challenges caused by the COVID-19
pandemic, regulatory delays, slower than anticipated patient enrollment,
manufacturing challenges, changing standards of care, evolving regulatory
requirements, clinical trial design, clinical outcomes and competitive factors;
(v) we may not achieve the expected costs savings we expect from the
restructuring and reorganization; and (vi) patents may not issue from our patent
applications for our drug candidates, patents that have issued may not be
enforceable, or additional intellectual property licenses from third parties may
be required; and (vii) certain other important risks and uncertainties set forth
in our Annual Report on Form 10-K filed with the
The information in this report is being furnished and shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section or Sections 11
and 12(a)(2) of the Securities Act of 1933, as amended. The information
contained in this report shall not be incorporated by reference into any other
filing with the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press release titled "Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
© Edgar Online, source